These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17021294)

  • 1. Response to 'Lapses at the NEJM'.
    Drazen JM
    J R Soc Med; 2006 Oct; 99(10):485; author reply 485. PubMed ID: 17021294
    [No Abstract]   [Full Text] [Related]  

  • 2. Lapses at the new England journal of medicine.
    Smith R
    J R Soc Med; 2006 Aug; 99(8):380-2. PubMed ID: 16893926
    [No Abstract]   [Full Text] [Related]  

  • 3. NEJM "failed its readers" by delay in publishing its concerns about VIGOR trial.
    Dobson R
    BMJ; 2006 Jul; 333(7559):116. PubMed ID: 16840463
    [No Abstract]   [Full Text] [Related]  

  • 4. NEJM stands by its criticism of Vioxx study.
    Tanne JH
    BMJ; 2006 Mar; 332(7540):505. PubMed ID: 16513694
    [No Abstract]   [Full Text] [Related]  

  • 5. Medical journal criticizes Merck over Vioxx data.
    Berenson A
    N Y Times Web; 2005 Dec; ():A1, C13. PubMed ID: 16456990
    [No Abstract]   [Full Text] [Related]  

  • 6. Selective COX-2 inhibitors: where do we go from here?
    Baigent C; Patrono C
    Lancet; 2008 Nov; 372(9651):1712-3. PubMed ID: 18922571
    [No Abstract]   [Full Text] [Related]  

  • 7. Adverse cardiovascular effects of rofecoxib.
    Furberg CD
    N Engl J Med; 2006 Jul; 355(2):204; author reply 204-5. PubMed ID: 16838442
    [No Abstract]   [Full Text] [Related]  

  • 8. Adverse cardiovascular effects of rofecoxib.
    Nissen SE
    N Engl J Med; 2006 Jul; 355(2):203-4; author reply 203-5. PubMed ID: 16801355
    [No Abstract]   [Full Text] [Related]  

  • 9. How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as "punching bag".
    Armstrong D
    Wall St J (East Ed); 2006 May; ():A1, A10. PubMed ID: 16848016
    [No Abstract]   [Full Text] [Related]  

  • 10. Time-to-event analyses for long-term treatments--the APPROVe trial.
    Lagakos SW
    N Engl J Med; 2006 Jul; 355(2):113-7. PubMed ID: 16801354
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug safety: are we making progress?: comment on "pooled analysis of rofecoxib placebo-controlled clinical trial data".
    Luepker RV
    Arch Intern Med; 2010 Jan; 170(2):202. PubMed ID: 20101016
    [No Abstract]   [Full Text] [Related]  

  • 12. NEJM editor gives pretrial evidence in Vioxx case.
    Tanne JH
    BMJ; 2006 Feb; 332(7536):255. PubMed ID: 16455704
    [No Abstract]   [Full Text] [Related]  

  • 13. Don't blame it all on the bogey.
    Day M
    BMJ; 2007 Jun; 334(7606):1250-1. PubMed ID: 17569929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Withdrawal of rofecoxib - a wake up call for drug safety.
    Mishra P; Palaian S
    Kathmandu Univ Med J (KUMJ); 2004; 2(4):360. PubMed ID: 16388250
    [No Abstract]   [Full Text] [Related]  

  • 15. Some key points emerging from the COX-2 controversy.
    Urquhart J
    Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):145-7. PubMed ID: 15654723
    [No Abstract]   [Full Text] [Related]  

  • 16. Persistence of cardiovascular risk after rofecoxib discontinuation.
    Ross JS; Madigan D; Konstam MA; Egilman DS; Krumholz HM
    Arch Intern Med; 2010 Dec; 170(22):2035-6. PubMed ID: 21149763
    [No Abstract]   [Full Text] [Related]  

  • 17. What have we learnt from Vioxx?
    Krumholz HM; Ross JS; Presler AH; Egilman DS
    BMJ; 2007 Jan; 334(7585):120-3. PubMed ID: 17235089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scientific publishing. Echoing other cases, NEJM says Vioxx Safety data withheld.
    Couzin J
    Science; 2005 Dec; 310(5755):1755. PubMed ID: 16357236
    [No Abstract]   [Full Text] [Related]  

  • 19. More bad news about anti-inflammatory agents.
    Haller C
    J Med Toxicol; 2005 Dec; 1(1):36-7. PubMed ID: 18072102
    [No Abstract]   [Full Text] [Related]  

  • 20. Bringing the FDA's Information to Market.
    Woloshin S; Schwartz LM
    Arch Intern Med; 2009 Nov; 169(21):1985-7. PubMed ID: 19933960
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.